哈药牌品牌怎么样 申请店铺

我要投票 哈药牌在补铁锌硒行业中的票数:32 更新时间:2024-11-24
哈药牌是哪个国家的品牌?「哈药牌」是 哈药集团有限公司 旗下著名品牌。该品牌发源于黑龙江,由创始人张利君在1989期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
哈药牌怎么样

哈药集团制药总厂始建于1958年,经过半个世纪的艰苦创业,不懈追求,已经由名不见经传的简陋小厂发展成为国内拥有先进理念、科学管理、核心竞争力的大型综合性制药企业,位列全国医药“百强”企业之首。年销售收入近50亿元,出口创汇1亿多美元。

公司主要生产青霉素类、头孢菌素类、大环内酯类抗生素以及心脑血管用药等30种原料药、原料中间体和100多种制剂品种。青霉素工业盐和7ACA两大母核的技术质量指标始终处于国内领先、国际一流水平。

企业拥有技术装备先进、管理体系完善的科研开发中心、质量检验中心、计控中心及生产、销售、服务等系统和职能部门,拥有精干、专业、严谨、高效的管理团队和敬业、忠诚、团结、向上的员工队伍。

企业先后自行研制开发了三类新药凯兰欣、铃兰欣、头孢吡肟、头孢替唑等,四类新药头孢唑肟钠、盐酸头孢替安、、盐酸头孢他美酯等几十种新产品。头孢替安无菌原料药是国内独家品种,获得了省科技进步奖、国家重点新稆证书;头孢美唑工艺技术的攻关成果获得国家重点新产品证书和医药行业科技进步一等奖。

企业的主导产品青霉素、头孢菌素类原粉和制剂均通过国家药品监督管理局GMP认证;青霉素工业钾盐通过了美国FDA认证;部分原料药和制剂通过南非卫生部的GMP认证;头孢唑林钠、头孢曲松钠原料药通过欧洲EDMF认证。

哈药集团制药总厂是中国重点抗生素生产和出口基地。营销系统下设九个销售公司,在全国29个省分布有62个办事处、600余名销售业务员,拥有5600多个经销商,产品覆盖除港澳台以外的所有区县。国际贸易营销网络覆盖中东、东南亚、南美、印度、俄罗斯以及原独联体其它国家、非洲、欧盟等市场,产品远销40多个国家和地区。

“哈药”品牌在2010年中国最有价值的品牌评价中,价值已达到160.62亿元,成为中国医药行业之冠和黑龙江省第一品牌。哈药集团制药总厂是国家级重合同守信用单位,哈药产品以优质、高效、安全在广大客户和消费者心目中享有盛誉。

哈药集团制药总厂秉承“厚德载物、兢兢以强”的企业精神,始终以发展和壮大祖国医药事业、造福人类健康为已任,孜孜以求,矢志超越,全力打造中国最具科技实力、经营潜力、发展张力、文化魅力的规范化、现代化、国际化的医药界强企,努力为社会、为人类创造更大的价值。

Harbin Pharmaceutical Group Pharmaceutical General Factory was founded in 1958. After half a century of hard work and unremitting pursuit, it has developed from a humble small factory to a large comprehensive pharmaceutical enterprise with advanced concept, scientific management and core competitiveness, ranking first among the "top 100" pharmaceutical enterprises in China. The annual sales revenue is nearly 5 billion yuan, and the export income is more than 100 million US dollars. The company mainly produces 30 kinds of APIs, raw material intermediates and more than 100 kinds of preparation varieties, such as penicillin, cephalosporins, macrolides antibiotics and cardio cerebrovascular drugs. The technical quality indexes of penicillin industrial salt and 7aca are always at the leading level in China and the first-class level in the world. The company has scientific research and development center, quality inspection center, planning and control center, production, sales, service and other systems and functional departments with advanced technology and equipment and perfect management system, and has a capable, professional, rigorous and efficient management team and dedicated, loyal, United and upward staff team. The company has developed three kinds of new drugs, kailanxin, suzulanxin, cefepime, ceftizole, and dozens of new products, including four kinds of new drugs, ceftizoxime sodium, cefotiam hydrochloride, ceftazidime hydrochloride, etc. Ceftriaxone sterile API is an exclusive product in China, which has won the provincial science and Technology Progress Award and the national key new product certificate; the research achievements of ceftriaxone technology have won the national key new product certificate and the first prize of science and technology progress in the pharmaceutical industry. The leading products of the enterprise are penicillin, cephalosporin raw powder and preparations, which have passed GMP certification of the State Drug Administration; potassium salt of penicillin industry has passed FDA certification of the United States; some APIs and preparations have passed GMP certification of the Ministry of health of South Africa; cefazolin sodium and ceftriaxone sodium raw materials have passed edmf certification of Europe. Harbin Pharmaceutical Group Pharmaceutical General Factory is a key antibiotic production and export base in China. The marketing system consists of nine sales companies, 62 offices in 29 provinces, more than 600 salespeople, and more than 5600 distributors, covering all districts and counties except Hong Kong, Macao and Taiwan. The international trade marketing network covers the markets of the Middle East, Southeast Asia, South America, India, Russia, other countries of the former CIS, Africa, EU, etc. its products are exported to more than 40 countries and regions. In 2010, the most valuable brand evaluation in China, the value of "Harbin Pharmaceutical" brand has reached 16.062 billion yuan, becoming the top of China's pharmaceutical industry and the first brand in Heilongjiang Province. Harbin Pharmaceutical Group Pharmaceutical Factory is a state-level contract abiding and trustworthy unit. Harbin pharmaceutical products enjoy a high reputation in the eyes of customers and consumers for their high quality, efficiency and safety. Harbin Pharmaceutical Group Pharmaceutical General Factory adheres to the enterprise spirit of "being virtuous and hardworking and strong", and always takes the development and expansion of the pharmaceutical industry of the motherland and the benefit of human health as its responsibility. It strives to surpass and strive to build a standardized, modern and international pharmaceutical industry with the most scientific and technological strength, business potential, development tension and cultural charm in China, striving to be a society and a person Class creates greater value.

本文链接: https://brand.waitui.com/2c2f753da.html 联系电话:0451-51961111-15262

千城特选小程序码

7×24h 快讯

上市公司回复可控核聚变概念最新动态:离商用发电还有较长距离

A股可控核聚变概念最近一周走强,东方精工、永鼎股份、弘讯科技等连续涨停。多家上市公司通过公告或互动易平台回复相关问题。①中国广核:公司关注并积极参与先进核能的研发工作,据了解,目前全球可控核聚变研发仍处于科学试验阶段,离实现商用发电还有较长距离。②海陆重工:公司拥有民用核安全设备制造许可证,可以承接核安全2、3的压力容器、热交换器。核聚变能源因其清洁、高效、可持续的特性,被视为解决未来能源危机的理想选择。国家未来的能源规划也明确提出可控核聚变是未来的主要发展方向。公司将抓住行业发展的机会,积极跟进行业动态,努力提高自身装备及技术水平,提高公司竞争力与盈利能力。③盛帮股份:公司核防护业务主要产品为个人穿戴式防护服、核工程类防护装备等。公司立足橡塑高分子材料改性研究,相关产品可应用于可控核聚变领域。④永鼎股份:公司下属控股子公司东部超导主营产品是第二代高温超导带材及超导应用产品,公司不直接生产制造可控核聚变装置,仅为绕制装置的磁体提供材料。目前,东部超导带材产量较少,2023年度营业收入占公司整体收入比重不足1%,且亏损,不会对公司业绩产生重大影响。(财联社)

14分钟前

共建广域低空通信网络试验场 上海市通管局与金山区签协议

11月21日,上海市通信管理局与金山区人民政府签署“共同建设广域低空通信网络试验场,打造一体化空天网”战略合作协议。双方将厚植金山全域数字化转型,发挥各自技术和资源优势,围绕支撑低空经济发展、推动区域数字化转型、持续优化营商环境、加强网络和数据安全保障等四个方面进行紧密合作。(e公司)

14分钟前

我国首条规模化民航轮胎生产线建成投产

我国首条规模化民航轮胎生产线在广西建成投产,每年可生产10万条高性能民用航空轮胎。(e公司)

14分钟前

仲景食品(南阳)有限公司揭牌暨一车间试产运营

据仲景食品消息,11月23日,仲景食品(南阳)有限公司揭牌暨一车间试产仪式举行。南阳产业园一期项目占地184亩,计划建设4个车间,其中一车间主要建设了以上海葱油为代表的调味酱汁类生产线,生产线采取了先进的自动化技术和智能化设备,在生产工艺和质量方面具有显著优势,将大幅提升公司的生产能力,满足日益增长的市场需求。(e公司)

14分钟前

知名私募温莎资本被注销登记

中国证券投资基金业协会11月22日公布了多份《纪律处分复核决定书》,部分私募不服纪律处分,向协会提出复核申请,协会均给予复核意见。值得注意的是,知名私募深圳温莎资本管理有限公司,因未及时报告办公地址变更信息、不配合自律检查工作等违规行为,被注销私募管理人登记。厦门京道产业投资基金管理有限公司(以下简称厦门京道)因存在虚假报送投资者信息、在管产品存在非合格投资者的违规事实,被协会公开谴责。(财联社)

14分钟前

本页详细列出关于养生堂的品牌信息,含品牌所属公司介绍,养生堂所处行业的品牌地位及优势。
咨询